Valuation: Laboratorio Reig Jofre SA

Market Cap 217M 0 247M 201M 185M 348M 23.85B 353M 2.39B 937M 11.67B 928M 908M 40.31B P/E 2026 *
13.3x
P/E 2027 * 22.2x
Enterprise Value 301M 0 344M 280M 257M 484M 33.18B 491M 3.33B 1.3B 16.23B 1.29B 1.26B 56.08B EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.75x
Free-Float
20.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 2005-12-31
Director of Finance/CFO - 2023-12-19
Chief Tech/Sci/R&D Officer - 2002-12-31
Director TitleAgeSince
Chairman - 2014-12-30
Director/Board Member 58 2014-12-30
Director/Board Member - 2017-11-06
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-.--% - - 247M
+2.20%+1.28%+48.22%+157.79% 1,037B
+1.77%+3.47%+52.95%+51.18% 615B
+1.97%+1.24%+35.16%+79.87% 448B
+5.70%+5.91%+34.40%+28.41% 326B
+1.05%+3.25%+36.66%+40.15% 293B
-0.16%+0.33%+18.70%+17.53% 264B
+0.25%-4.62%-27.66%-41.76% 216B
+0.77%-0.78%+19.23%+56.61% 198B
+0.03%-4.33%+14.83%+67.91% 162B
Average +1.59%+1.12%+25.83%+50.86% 395.27B
Weighted average by Cap. +1.83%+1.47%+35.26%+75.81%

Financials

2026 *2027 *
Net sales 365M 0 416M 339M 311M 587M 40.19B 595M 4.04B 1.58B 19.66B 1.56B 1.53B 67.93B 392M 0 447M 364M 334M 630M 43.16B 639M 4.33B 1.7B 21.12B 1.68B 1.64B 72.95B
Net income 16.7M 0 19.06M 15.5M 14.25M 26.84M 1.84B 27.24M 185M 72.29M 900M 71.55M 70.01M 3.11B 9.5M 0 10.84M 8.82M 8.1M 15.27M 1.05B 15.5M 105M 41.12M 512M 40.7M 39.82M 1.77B
Net Debt 84.7M 0 96.67M 78.63M 72.26M 136M 9.33B 138M 937M 367M 4.56B 363M 355M 15.77B 78.7M 0 89.82M 73.06M 67.14M 127M 8.67B 128M 870M 341M 4.24B 337M 330M 14.65B
Logo Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
-